Doxorubicin + ifosfamide (advanced/metastatic MPNST, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-DOXORUBICIN DRUG-IFOSFAMIDE |
|---|
| ID | REG-DOXORUBICIN-IFOSFAMIDE-MPNST |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-SARCOMA |
Notes
STUB scaffold. Dosing summary only.
Used By
Indication
IND-MPNST-DOXORUBICIN-IFOSFAMIDE- IND-MPNST-DOXORUBICIN-IFOSFAMIDE
Regimen
REG-DOXORUBICIN-IFOSFAMIDE-STS- Doxorubicin + ifosfamide (soft tissue sarcoma, AI regimen)